Long-Term Clinical Follow-Up after Drug-Eluting Stent Implantation for Bare Metal In-Stent Restenosis

Berta, Balázs and Ruzsa, Zoltán and Bárczi, György and Becker, Dávid and Gellér, László Alajos and Jambrik, Zoltán and Molnár, Levente Domonkos and Szabó, György and Merkely, Béla Péter (2013) Long-Term Clinical Follow-Up after Drug-Eluting Stent Implantation for Bare Metal In-Stent Restenosis. JOURNAL OF INTERVENTIONAL CARDIOLOGY, 26 (3). pp. 271-277. ISSN 0896-4327

Text BERTA_et_al_2013_Journal_of_Interventional_Cardiology_u.pdf Restricted to Registered users only Download (142kB) | Request a copy

Abstract

OBJECTIVES: We aimed to evaluate the long-term safety and efficacy of drug-eluting stent (DES) implantation in the treatment of diffuse bare metal stent (BMS) restenosis as compared to the treatment of de novo coronary lesions in high restenosis risk patient population. BACKGROUND: To date limited long-term data are available about the treatment of BMS restenosis with DES. METHODS: Five hundred and fourteen consecutive patients who underwent DES implantation between January 2003 and October 2006 at our institute were studied: 201 patients received DES for treatment of BMS restenosis and 313 patients received DES for high restenosis risk de novo lesions. Outcomes were calculated using propensity score adjustment. Mean follow-up length was 45.6 +/- 21.5 months. RESULTS: The rates of acute coronary syndrome, three-vessel disease, and diabetes were high in both restenosis and de novo groups: 44.8% versus 46.3%, 20.9% versus 28.7%, and 34.3% versus 38.9%, respectively. The incidence of ischemia-driven target lesion revascularization (TLR) yielded similar results in the restenosis group and de novo group at 4 years (10.4% vs 12.4%, P = 0.490). All-cause mortality was lower in the restenosis group at 4 years (7.4% vs 14.7%, P = 0.032); however, the incidence of definite and probable stent thrombosis did not differ (1.9% vs 1.6%, P = 0.708) between the 2 groups. CONCLUSIONS: DESs are safe in the treatment of diffuse BMS restenosis and the rate of additional TLR is acceptable as compared to the use of DES in de novo lesions.

Actions (login required)

Edit Item